Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Winsome Cheung is an associate in Covington’s life sciences transactional group.

Ms. Cheung assists clients in the life sciences sector on their strategic transactions and investments, and intellectual property and commercial matters relating to the discovery, development, and commercialization of their products.

Ms. Cheung has a particular focus on the structuring, drafting, and negotiation of collaboration, co-development, license, and other complex strategic agreements, as well as manufacturing, clinical trial, and other agreements fundamental to the day-to-day running of life sciences businesses. Ms. Cheung also advises on intellectual property and commercial aspects of M&A transactions and venture capital investments.

  • Illumina on its partnership with Genomics England, to sequence up to 500,000 whole genomes for the NHS Genomic Medicine Service. 
  • AstraZeneca on its strategic oncology collaboration with Innate Pharma S.A.
  • Breath Therapeutics B.V. and existing shareholders Gimv, Sofinnova Partners, Gilde Healthcare and founders on the sale of Breath Therapeutics to Zambon for up to a total of €500 million subject to regulatory and sales milestones with an upfront payment of €140 million.
  • Ziylo Ltd on its acquisition by Novo Nordisk, and the spin out of certain Ziylo assets to a new company, which involved an exclusive license granted by Ziylo to Carbometrics to develop applications in diagnostics and continuous glucose monitoring, and a research agreement between Ziylo and Carbometrics.
  • Autifony Therapeutics Limited on an option and asset purchase agreement with Boehringer Ingelheim (BI), which provides BI with an exclusive option to acquire Autifony’s Kv3.1/3.2 positive modulator platform.
  • GammaDelta Therapeutics Limited on:
    • a strategic collaboration with Takeda to develop GammaDelta Therapeutics’ novel T cell platform, which is based on the unique properties of gamma delta (γδ) T cells derived from human tissues; and
    • its acquisition of Lymphact, a Portuguese based company focused on developing innovative personalised medical treatments.
  • Illumina on its strategic alliance agreement with Genomics England in respect of sequencing genomes of patients with cancer and rare diseases, as part of a UK government project to decode 100,000 human genomes.
  • Abingworth on the establishment of and investment in GammaDelta Therapeutics Ltd, an immunotherapy company.
  • AstraZeneca on its acquisition of the core respiratory business of Takeda.
  • AstraZeneca on an agreement with ProStrakan Group, for the rights to Moventig in the European Union, Iceland, Norway, Switzerland, and Liechtenstein.
  • Allergy Therapeutics in connection with a license agreement with respect of virus-like particle technology.